Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) (NYSE: BDX) will release its financial results for Q1 of fiscal year 2022 on February 3, 2022, at 6 a.m. ET. The announcement will include summary financial data for the quarter ending December 31, 2021. Following the release, management will host an audio webcast at 8 a.m. ET to discuss results and operational strategies. For further details and the live audio link, visit www.bd.com/investors. BD is committed to advancing healthcare through innovative technology and solutions.
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent medical technology leader, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. Eastern Time. The presentation will be accessible via live webcast on BD's investor relations website, with a replay available afterward. BD focuses on advancing health through technology, diagnostics, and care delivery, supporting healthcare providers and enhancing patient outcomes globally.
BD (Becton, Dickinson and Company) has launched the BD Veritor™ At-Home COVID-19 Test, now available through Everly Health and Southeastern Grocers, including Fresco y Más, Harveys Supermarket, and Winn-Dixie. The test is unique as it utilizes a smartphone app to interpret results, ensuring accuracy without human error. BD emphasizes the test's importance for community safety amidst rising COVID-19 cases, especially during the holiday season. The test is available online and in-store, enabling broad access for consumers.
BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.
BD (Becton, Dickinson and Company) has successfully acquired Scanwell Health Inc., a pioneer in smartphone-enabled at-home medical testing. The acquisition aims to enhance BD's digital capabilities for at-home diagnostics, including COVID-19 and other infectious diseases. The BD Veritor™ At-Home COVID-19 Test leverages smartphone technology for accurate result interpretation. Although transaction details were not disclosed, it is anticipated to have an immaterial impact on BD's fiscal 2022 financials. This move underscores BD's commitment to innovative health solutions.
BD (Becton, Dickinson and Company) (NYSE: BDX) has expanded its BD COR™ System with the introduction of the MX instrument, designed for high-throughput molecular testing for infectious diseases, including a new CE-marked assay for sexually transmitted infections. The MX instrument, part of a modular system alongside the PX and GX instruments, can process 1,700 specimens and deliver up to 1,000 results in 24 hours, enhancing laboratory efficiency. The platform automates testing workflows, improving diagnostics for women's health and STIs.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
BD (Becton, Dickinson and Company) announced that the new name for its upcoming spinoff of the Diabetes Care business will be embecta. This independent, publicly-traded company aims to empower those living with diabetes while maintaining a connection to BD's legacy. The spinoff is expected to finalize in the second quarter of 2022. Devdatt Kurdikar will serve as CEO, leading a diverse team focused on innovation and improvement in diabetes care products. The name reflects the company's commitment and heritage, aiming to enhance the quality of life for diabetes patients globally.
BD (Becton, Dickinson and Company) has acquired Venclose, Inc., a leader in treatments for chronic venous insufficiency (CVI). This acquisition enhances BD's portfolio of venous disease technologies, leveraging Venclose's innovative Radio Frequency (RF) ablation system that is designed for efficiency and versatility. CVI affects up to 40% of women and 17% of men in the U.S. The dual heating length of the Venclose System allows multiple vein segments to be ablated with one catheter, potentially reducing post-operative pain for patients. The financial impact of the deal is expected to be immaterial for BD's fiscal 2022.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
